Michelle LaSpaluto
Director of Finance/CFO bij CHIMERIX, INC.
Vermogen: 117 659 $ op 31-03-2024
Profiel
Michelle LaSpaluto is currently the Chief Financial Officer at Chimerix, Inc. since 2023.
Previously, she worked as the Senior Director-Accounting at AlphaVax, Inc. from 2000 to 2011.
Ms. LaSpaluto completed her undergraduate degree at Michigan State University and holds an MBA from East Carolina University.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
CHIMERIX, INC.
0.12% | 14-02-2024 | 110 999 ( 0.12% ) | 117 659 $ | 31-03-2024 |
Actieve functies van Michelle LaSpaluto
| Bedrijven | Functie | Begin |
|---|---|---|
| CHIMERIX, INC. | Director of Finance/CFO | 01-12-2023 |
Eerdere bekende functies van Michelle LaSpaluto
| Bedrijven | Functie | Einde |
|---|---|---|
AlphaVax, Inc.
 AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Comptroller/Controller/Auditor | 01-06-2011 |
Opleiding van Michelle LaSpaluto
| Michigan State University | Undergraduate Degree |
| East Carolina University | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CHIMERIX, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
AlphaVax, Inc.
AlphaVax, Inc. Pharmaceuticals: MajorHealth Technology AlphaVax, Inc. involves in clinical-stage biopharmaceutical company. It develops vaccine technology bio products. The firm products include Alphavax and pipleline bio products. It focuses on commercial potential of its alphavaccine vector technology in cancer immunotherapy. The company was founded in 1997 and is headquartered in Durham, NC. | Health Technology |
